Patients with bipolar II disorder benefit from single dose of psilocybin
The Brown University Psychopharmacology Update March 4, 2024 DOI: 10.1002/pu.31143 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Open-label nonrandomized trial Peer reviewed |
|---|---|
| Sample size | 15 |
| Population | Adults with bipolar II disorder |
| Intervention | Psilocybin |
| Dose | 25 mg |
| Duration | 12-week endpoint |
| Topics | Psilocybin |
| Keywords | Bipolar disorder Pharmacology Hallucinogen Cognition |
| Key findings | A single 25 mg dose of psilocybin improved depressive symptoms in all 15 participants, with 12 meeting response and remission criteria at 12 weeks. |
Abstract
A single 25‐mg dose of psilocybin resulted in improvement in depressive symptoms in all 15 participants in an open‐label nonrandomized trial enrolling adults with bipolar II disorder. Twelve of the 15 participants met response and remission criteria at the study's 12‐week endpoint.